LCMS/MS METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTIFICATION OF SIMEPREVIR IN HUMAN PLASMA.

Abstract

To validate the procedure for estimation of Simeprevir Human K2EDTA plasma using LC-MS/MS. This study points to build up and validate a simple method logy to
quantify the most used drug simeprevir for the treatment of hepatitis C virus (HCV) infection, in human plasma by using Simeprevir and Simeprevir-D6 as an internal
Standard (IS) for preclinical studies a validated as per USFDA guidelines the determination of Amprenavir using an Quattro Premier XE LC-MS/MS coupled with 2695
HPLC separation module, a Xterra MS C18 (100 × 4.6 mm, 3.5µm) column and an SPD-M20A PDA detector.